Gustavo A Heresi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7083854/publications.pdf

Version: 2024-02-01

331670 345221 1,439 61 21 36 citations h-index g-index papers 62 62 62 1850 all docs docs citations times ranked citing authors

#	Article	IF	CITATIONS
1	Off-Label Use and Inappropriate Dosing of Direct Oral Anticoagulants in Cardio-pulmonary Disease. Chest, 2022, , .	0.8	3
2	Identifying Patients with Group 3 Pulmonary Hypertension Associated with COPD or ILD Using an Administrative Claims Database. Lung, 2022, 200, 187-203.	3.3	2
3	Assessment for residual disease after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension. ERJ Open Research, 2022, 8, 00572-2021.	2.6	2
4	Estrogen Signaling and Portopulmonary Hypertension: The Pulmonary Vascular Complications of Liver Disease Study (PVCLD2). Hepatology, 2021, 73, 726-737.	7.3	24
5	Incidence of symptomatic venous thromboembolism following hospitalization for coronavirus disease 2019: Prospective results from a multi-center study. Thrombosis Research, 2021, 198, 135-138.	1.7	50
6	Acute pulmonary embolism multimodality imaging prior to endovascular therapy. International Journal of Cardiovascular Imaging, 2021, 37, 343-358.	1.5	6
7	Abnormal levels of apolipoprotein Aâ€i in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2021, 11, 1-7.	1.7	6
8	Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension. Journal of Thrombosis and Thrombolysis, 2021, 52, 791-796.	2.1	6
9	Bilateral Pulmonary Emboli and Deep Venous Thrombi in Association With Chronic Inflammatory Demyelinating Polyneuropathy. Cureus, 2021, 13, e14802.	0.5	O
10	Is pulmonary vascular resistance index better than pulmonary vascular resistance in predicting outcomes in pulmonary arterial hypertension?. Journal of Heart and Lung Transplantation, 2021, 40, 614-622.	0.6	4
11	Optimal Tricuspid Regurgitation Velocity to Screen for Pulmonary Hypertension in Tertiary Referral Centers. Chest, 2021, 160, 2209-2219.	0.8	5
12	Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. Journal of Heart and Lung Transplantation, 2021, 40, 1301-1326.	0.6	36
13	The breath print represents a novel biomarker of malnutrition in pulmonary arterial hypertension: a proofâ€ofâ€concept study. Journal of Parenteral and Enteral Nutrition, 2021, 45, 1645-1652.	2.6	2
14	Liver abnormalities in pulmonary arterial hypertension. Pulmonary Circulation, 2021, 11, 1-12.	1.7	12
15	Pulmonary embolism response teams: A concept in progress and beyond borders. Kardiologia Polska, 2021, 79, 1301-1302.	0.6	1
16	Morphologic and Functional Dual-Energy CT Parameters in Patients With Chronic Thromboembolic Pulmonary Hypertension and Chronic Thromboembolic Disease. American Journal of Roentgenology, 2020, 215, 1335-1341.	2.2	6
17	Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension. Lung, 2020, 198, 933-938.	3.3	14
18	COVID-19 and Pulmonary Arterial Hypertension: Early Data and Many Questions. Annals of the American Thoracic Society, 2020, 17, 1528-1530.	3.2	19

#	Article	IF	Citations
19	Comparison of 4 Acute Pulmonary Embolism Mortality Risk Scores in Patients Evaluated by Pulmonary Embolism Response Teams. JAMA Network Open, 2020, 3, e2010779.	5.9	26
20	CT-Based Biomarkers for Prediction of Chronic Thromboembolic Pulmonary Hypertension After an Acute Pulmonary Embolic Event. American Journal of Roentgenology, 2020, 215, 800-806.	2.2	16
21	Refining Risk Stratification in Pulmonary Embolism. Chest, 2020, 158, 858-859.	0.8	1
22	Assessment of ventilation-perfusion scans in patients with chronic thromboembolic pulmonary hypertension before and after surgery and correlation with clinical parameters. Clinical Imaging, 2020, 66, 147-152.	1.5	4
23	Mixed Venous Oxygen Saturation Is a Better Prognosticator Than Cardiac Index in Pulmonary Arterial Hypertension. Chest, 2020, 158, 2546-2555.	0.8	11
24	Lipids and ketones dominate metabolism at the expense of glucose control in pulmonary arterial hypertension: a hyperglycaemic clamp and metabolomics study. European Respiratory Journal, 2020, 55, 1901700.	6.7	28
25	Sobre las recomendaciones del Ministerio de Salud para el tratamiento farmacológico de la COVID-19 en el Perú. Acta Medica Peruana, 2020, 37, .	0.1	7
26	Plasma metabolomic profile in chronic thromboembolic pulmonary hypertension. Pulmonary Circulation, 2020, 10, 2045894019890553.	1.7	11
27	Impact of Multidisciplinary Pulmonary Embolism Response Team Availability on Management and Outcomes. American Journal of Cardiology, 2019, 124, 1465-1469.	1.6	107
28	Pulmonary Edema Following Initiation of Parenteral Prostacyclin Therapy for Pulmonary Arterial Hypertension. Chest, 2019, 156, 45-52.	0.8	5
29	Evaluation of Vascular Parameters in Patients With Pulmonary Thromboembolic Disease Using Dual-energy Computed Tomography. Journal of Thoracic Imaging, 2019, 34, 367-372.	1.5	12
30	A multidisciplinary pulmonary embolism response team (PERT)â€"experience from a national multicenter consortium. Pulmonary Circulation, 2019, 9, 1-10.	1.7	45
31	Caught in the Act: Thrombus Wedged in a Patent Foramen Ovale. American Journal of Medicine, 2018, 131, 927-930.	1.5	O
32	Comparative assessment of qualitative and quantitative perfusion with dual-energy CT and planar and SPECT-CT V/Q scanning in patients with chronic thromboembolic pulmonary hypertension. Cardiovascular Diagnosis and Therapy, 2018, 8, 414-422.	1.7	33
33	Pulmonary Embolism Response Teams: A Novel Approach for the Care of Complex Patients With Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis, 2018, 24, 48S-55S.	1.7	20
34	A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic. Journal of Thrombosis and Thrombolysis, 2018, 46, 186-192.	2.1	36
35	Plasma levels of high density lipoprotein cholesterol and outcomes in chronic thromboembolic pulmonary hypertension. PLoS ONE, 2018, 13, e0197700.	2.5	14
36	Survival After an ICU Hospitalization for Pulmonary Hypertension. Chest, 2018, 154, 229-231.	0.8	8

#	Article	IF	CITATIONS
37	Diagnosis of Deep Venous Thrombosis and Pulmonary Embolism. Clinics in Chest Medicine, 2018, 39, 493-504.	2.1	12
38	Hypoxemia in patients with idiopathic or heritable pulmonary arterial hypertension. PLoS ONE, 2018, 13, e0191869.	2.5	17
39	Pulmonary embolism response teams. Journal of Thrombosis and Thrombolysis, 2017, 44, 19-29.	2.1	19
40	Healthcare burden of pulmonary hypertension owing to lung disease and/or hypoxia. BMC Pulmonary Medicine, 2017, 17, 58.	2.0	23
41	Pulmonary thromboendarterectomy in the setting of a mediastinal venous malformation with a congenitally absent left subclavian vein. Pulmonary Circulation, 2017, 7, 256-260.	1.7	4
42	Abnormal Glucose Metabolism and High-Energy Expenditure in Idiopathic Pulmonary Arterial Hypertension. Annals of the American Thoracic Society, 2017, 14, 190-199.	3.2	36
43	Diversity in the Pulmonary Embolism Response Team Model. Chest, 2016, 150, 1414-1417.	0.8	72
44	Novel Methods in Pulmonary Hypertension Phenotyping in the Age of Precision Medicine (2015 Grover) Tj ETQq0	00.0 rgBT	/Oyerlock 10
45	Chronic Thromboembolic Pulmonary Hypertension: A Worldwide View of How Far We Have Come. Lung, 2016, 194, 483-485.	3.3	2
46	Thrombolysis in submassive pulmonary embolism: Finding the balance. Cleveland Clinic Journal of Medicine, 2016, 83, 933-936.	1.3	3
47	<i>O</i> -Linked \hat{I}^2 - <i>N</i> -Acetylglucosamine Transferase Directs Cell Proliferation in Idiopathic Pulmonary Arterial Hypertension. Circulation, 2015, 131, 1260-1268.	1.6	48
48	The outstanding diagnosis. Journal of Emergencies, Trauma and Shock, 2015, 8, 244.	0.7	0
49	Causes and Circumstances of Death in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 365-369.	5.6	186
50	Clinical Characterization and Survival of Patients with Borderline Elevation in Pulmonary Artery Pressure. Pulmonary Circulation, 2013, 3, 916-925.	1.7	49
51	A 70-Year-Old Woman With Acute Right Ventricular Failure and Circulatory Collapse. Chest, 2012, 141, 259-264.	0.8	0
52	Prevalence and Prognostic Value of Left Ventricular Diastolic Dysfunction in Idiopathic and Heritable Pulmonary Arterial Hypertension. Chest, 2012, 141, 1457-1465.	0.8	66
53	Serum High-Density Lipoprotein Cholesterol Levels as a Prognostic Indicator in Patients With Idiopathic Pulmonary Arterial Hypertension. American Journal of Cardiology, 2012, 110, 433-439.	1.6	32
54	Strengths and Limitations of the Six-Minute-Walk Test. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1122-1124.	5.6	37

#	Article	IF	CITATIONS
55	CXC-Chemokine Ligand 10 in Idiopathic Pulmonary Arterial Hypertension: Marker of Improved Survival. Lung, 2010, 188, 191-197.	3.3	26
56	Plasma Levels of High-Density Lipoprotein Cholesterol and Outcomes in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 661-668.	5.6	112
57	Interstitial Pneumonitis and Alveolar Hemorrhage Complicating Use of Rituximab. Respiration, 2008, 76, 449-453.	2.6	44
58	Lupus-associated pulmonary hypertension: Long-term response to vasoactive therapy. Respiratory Medicine, 2007, 101, 2099-2107.	2.9	29
59	Pulmonary Hypertension: Evaluation and Management. Comprehensive Therapy, 2007, 33, 150-161.	0.2	12
60	Pulmonary Artery Catheter and Fluid Management in Acute Lung Injury and the Acute Respiratory Distress Syndrome. Clinics in Chest Medicine, 2006, 27, 627-635.	2.1	17
61	Multiple pulmonary nodules in an elderly woman. Journal of Thoracic Oncology, 2006, 1, 580-1.	1.1	0